Article
Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of…
OncoTargets and Therapy · 2018 · Feldheim J, Kessler AF, Schmitt D, Wilczek L, Linsenmann T, Dahlmann M, Monoranu CM, Ernestus RI, Hagemann C, Löhr M
Key facts
| Title | Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of different WHO grades and correlates with survival of glioblastoma patients |
|---|---|
| First author | Feldheim J, Kessler AF, Schmitt D, Wilczek L, Linsenmann T, Dahlmann M, Monoranu CM, Ernestus RI, Hagemann C, Löhr M |
| Journal | OncoTargets and Therapy |
| Published | Dec 4, 2018 |
| DOI | 10.2147/OTT.S176549 |
| Devices mentioned | K040782, K852441, K854177, K854178, K854179, K854180, K854181, K854182, K854183, K854184, K854185, K854186 and 2 more |
| Product codes mentioned | CDT, CEO, CGA, CGX, CHH, CIG, CIS, CIX, CJE, CKA, JAK, KLB and 2 more |
At a glance
- 10–99 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1